These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 28705172)

  • 1. Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss.
    Dawson AJ; Kilpatrick ES; Coady AM; Elshewehy AMM; Dakroury Y; Ahmed L; Atkin SL; Sathyapalan T
    BMC Endocr Disord; 2017 Jul; 17(1):41. PubMed ID: 28705172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocannabinoid receptor blockade increases vascular endothelial growth factor and inflammatory markers in obese women with polycystic ovary syndrome.
    Sathyapalan T; Javed Z; Kilpatrick ES; Coady AM; Atkin SL
    Clin Endocrinol (Oxf); 2017 Mar; 86(3):384-387. PubMed ID: 27651218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of 8 months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome.
    Preiss D; Sattar N; Harborne L; Norman J; Fleming R
    Int J Clin Pract; 2008 Sep; 62(9):1337-43. PubMed ID: 18565127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome.
    Cho LW; Kilpatrick ES; Keevil BG; Coady AM; Atkin SL
    Clin Endocrinol (Oxf); 2009 Feb; 70(2):233-7. PubMed ID: 18547343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin maintains the weight loss and metabolic benefits following rimonabant treatment in obese women with polycystic ovary syndrome (PCOS).
    Sathyapalan T; Cho LW; Kilpatrick ES; Coady AM; Atkin SL
    Clin Endocrinol (Oxf); 2009 Jan; 70(1):124-8. PubMed ID: 19128368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study.
    Sathyapalan T; Cho LW; Kilpatrick ES; Coady AM; Atkin SL
    Clin Endocrinol (Oxf); 2008 Dec; 69(6):931-5. PubMed ID: 18410553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocannabinoid receptor blockade increases hepatocyte growth factor and reduces insulin levels in obese women with polycystic ovary syndrome.
    Sathyapalan T; Dakroury Y; Ahmed L; Elshewehy AM; Kilpatrick ES; Coady AM; Atkin SL
    Clin Endocrinol (Oxf); 2016 Oct; 85(4):671-3. PubMed ID: 27256522
    [No Abstract]   [Full Text] [Related]  

  • 9. Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome.
    Koiou E; Tziomalos K; Katsikis I; Delkos D; Tsourdi EA; Panidis D
    Hormones (Athens); 2013; 12(4):559-66. PubMed ID: 24457404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel effects of the cannabinoid inverse agonist AM 251 on parameters related to metabolic syndrome in obese Zucker rats.
    Merroun I; Sánchez-González C; Martínez R; López-Chaves C; Porres JM; Aranda P; Llopis J; Galisteo M; Zarzuelo A; Errami M; López-Jurado M
    Metabolism; 2013 Nov; 62(11):1641-50. PubMed ID: 23932644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment.
    Ciaraldi TP; Aroda V; Mudaliar SR; Henry RR
    Metabolism; 2013 Nov; 62(11):1587-96. PubMed ID: 23958241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
    Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
    Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the cannabinoid receptor-1 antagonist rimonabant on inflammation in mice with diet-induced obesity.
    Wang Q; Perrard XD; Perrard JL; Mansoori A; Smith CW; Ballantyne CM; Wu H
    Obesity (Silver Spring); 2011 Mar; 19(3):505-13. PubMed ID: 20885384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity.
    Tam J; Godlewski G; Earley BJ; Zhou L; Jourdan T; Szanda G; Cinar R; Kunos G
    Am J Physiol Endocrinol Metab; 2014 Feb; 306(4):E457-68. PubMed ID: 24381003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis.
    Hsiao WC; Shia KS; Wang YT; Yeh YN; Chang CP; Lin Y; Chen PH; Wu CH; Chao YS; Hung MS
    Diabetes Obes Metab; 2015 May; 17(5):495-504. PubMed ID: 25656402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonism of the cannabinoid CB-1 receptor protects rat liver against ischaemia-reperfusion injury complicated by endotoxaemia.
    Caraceni P; Pertosa AM; Giannone F; Domenicali M; Grattagliano I; Principe A; Mastroleo C; Perrelli MG; Cutrin J; Trevisani F; Croci T; Bernardi M
    Gut; 2009 Aug; 58(8):1135-43. PubMed ID: 19282305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effect of rimonabant, a canabinoid receptor 1 antagonist, on nonalcoholic fatty liver disease in a rat model through modulation of the hepatic expression of activin A and follistatin.
    Hussien NI; El-Kerdasy HI; Ibrahim ME
    Can J Physiol Pharmacol; 2017 Dec; 95(12):1433-1441. PubMed ID: 28759733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome.
    Targher G; Solagna E; Tosi F; Castello R; Spiazzi G; Zoppini G; Muggeo M; Day CP; Moghetti P
    J Endocrinol Invest; 2009 Sep; 32(8):695-700. PubMed ID: 19542757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of cannabinoid receptor 1 blockade on adipokine and proinflammatory cytokine concentration in adipose and hepatic tissue in mice with nonalcoholic fatty liver disease.
    Jorgačević B; Vučević D; Vesković M; Mladenović D; Vukićević D; Vukićević RJ; Todorović V; Radosavljević T
    Can J Physiol Pharmacol; 2019 Feb; 97(2):120-129. PubMed ID: 30673308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
    Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR
    Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.